BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » ReeLabs Approved to Conduct First and Only Stem Cell Trial Against COVID-19 in India
Stem cells covid-19 India

ReeLabs Approved to Conduct First and Only Stem Cell Trial Against COVID-19 in India

October 11, 2020 By Cade Hildreth (CEO) Leave a Comment

ReeLabs received permission from the Central Licensing Authority to conduct the first and only  trial in India using MSCs from placenta and umbilical cord tissue against COVID-19.

There are numerous publications that have documented the role of stem cell against COVID-19. Currently there are 23 stem cell trials in progress in US, UK, Japan, Germany, China, Spain, France and various other developed countries and hitherto published literature is extremely encouraging.

Discover class-defining bioproduction tools.

India is now all set to join this elite list.

In a significant, potentially path-breaking development, ReeLabs Private Limited, India’s biggest stem cell banking and research company, has been approved by Central Drugs Standard Control Organisation (CDSCO) and Drugs Controller General of India (DCGI) to conduct a stem cell trial against COVID-19, the first one in India.

ReeLabs to Conduct 1st Stem Cell Trial Against COVID-19

The trial is registered with the Clinical Trial Registry of India (CTRI) and will use intravenous administration of a patented stem cell product (mixture of umbilical cord and placenta derived mesenchymal stem cells) obtained from ReeLabs.

In Phase I of the project, out of the 20 patients selected  in the moderate to severe category, 10 will get 100 million mesenchymal stem cells (MSCS) and the remaining 10 will get 200 million stem cells. The cells will be injected intravenously over forty minutes with a speed of 40 drops per minute.

ReeLabs has recently been granted two US patents that describe their technology in detail.

The reason why moderate to severe patients deteriorate clinically to become severely critical is due to the ‘Cytokine storm’. MSCs by the virtue of their paracrine mechanisms reduce the harmful effect of the Cytokine storm by: (i) reducing the level of the harmful pro-inflammatory cytokine TNF-alpha and (ii) increasing the level of the protective anti-inflammatory cytokines IL-10. MSCs also improve the pulmonary microenvironment and lung function by differentiating into different types of alveolar epithelial cells.

Dr. Abhijit Bopardikar MD, Director ReeLabs states:

“The sheer magnitude of the COVID-19 pandemic has sent shock waves throughout the world due to which ReeLabs has immediately recalibrated its priorities. We are delighted to be involved in two significant clinical trials against COVID-19, using our patented product (mixture of cultured placental and Cord derived mesenchymal cells) and using Convalescent Plasma. The world has started serious activity to overcome the devastation and India cannot be left behind. In fact we would like to lead the way whilst working out tangible solutions to treat multitude of both, actively infected patients of COVID-19 as well as patients suffering from post COVID-19 complications. The result of these trials shall be major milestones for the Asian subcontinent.”

Leveraging Stem Cells Against COVID-19

ReeLabs has offered to supply the patented stem cell product for free to all patients infected by COVID- 19 in the country even after completion of the study. Given that India has a population of 1.4 billion, representing approximately 18% of the global population of 7.8 billion, this is a major commitment.

Group ReeLabs, Mumbai, India is the largest, state-of-the-art stem cell enterprise of Asia covering over 5000 square meter of laboratory space. The enterprise has launched two FDA approved clinical trials.

To learn more about the therapeutic and commercial applications of cord blood and tissue, view the “Global Cord Blood Banking Industry Report 2020.”

5 / 5 ( 7 votes )

Filed Under: Cord Blood, Coronavirus (COVID-19)

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Vitro Biopharma

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

MSC market

How the MSC Market is Coming of Age in 2021

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.